Longworth, M; Banister, SD; Mack, JBC; Glass, M; Connor, M; Kassiou, M. The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities. Forensic Toxicol., 1 Jul 2016, 34 (2), 286–303. 1.3 MB. https://doi.org/10.1007/s11419-016-0316-y #1
Potter, DJ; Hammond, K; Tuffnell, S; Walker, C; Forti, MD. Potency of Δ9-tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: Implications for public health and pharmacology. Drug Test. Anal., 1 Apr 2018, 10 (4), 628–635. 470 kB. https://doi.org/10.1002/dta.2368
Collins, M. Some new psychoactive substances: Precursor chemical and synthesis-driver end-products. Drug Test. Anal., 1 Jul 2001, 3 (7–8), 404–416. 178 kB. https://doi.org/10.1002/dta.315
Desai, RI; Thakur, GA; Vemuri, VK; Bajaj, S; Makriyannis, A; Bergman, J. Analysis of Tolerance and Behavioral/Physical Dependence during Chronic CB1 Agonist Treatment: Effects of CB1 Agonists, Antagonists, and Noncannabinoid Drugs. J. Pharmacol. Exp. Ther., 29 Nov 2012, 344 (2), 319-328. 1.1 MB. https://doi.org/10.1124/jpet.112.198374
Oh, S; Kim, KS; Chung, YS; Shong, M; Park, SB. Anti-obesity agents: A focused review on the structural classification of therapeutic entities. Curr. Top. Med. Chem., 1 Apr 2009, 9 (6), 466–481. 438 kB. https://doi.org/10.2174/156802609788897862
Shulgin, AT. Chemistry of psychotomimetics. In Handbook of Experimental Pharmacology. Psychotropic Agents, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs; Hoffmeister, F; Stille, G, Eds., Springer-Verlag, Berlin, 1 Jan 1982; Vol. 55 (3), pp 3–29. 928 kB. https://doi.org/10.1007/978-3-642-67770-0_1 #20a
Shulgin, AT. Basic Pharmacology and Effects. In Hallucinogens. A Forensic Drug Handbook; Laing, R; Siegel, JA, Eds., Academic Press, London, 24 Apr 2003; pp 67–137. 6.3 MB.
Shulgin, AT. Hallucinogens. In Burger’s Medicinal Chemistry, 4th ed., Part III; Wolff, ME, Ed., John Wiley & Sons, Inc., 1 Jan 1981; pp 1109–1137. 4.7 MB. #53
Shulgin, AT. Psychotomimetic agents. In Psychopharmacological Agents; Gordon, M, Ed., Academic Press, New York, 1 Jan 1976; Vol. 4, pp 59–146. 3.1 MB. #LXXXVIII
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: Origins. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 165-190. 906 kB. https://doi.org/10.1007/164_2018_143 #1
Russo, EB; Marcu, J. Cannabis pharmacology: The usual suspects and a few promising leads. In Adv. Pharmacol.; , Elsevier, 1 Jan 2017; pp 67–134. 1.6 MB. https://doi.org/10.1016/bs.apha.2017.03.004 #delta-9-Tetrahydrocannabinol
Floresta, G; Apirakkan, O; Rescifina, A; Abbate, V. Discovery of high-affinity cannabinoid receptors ligands through a 3D-QSAR ushered by scaffold-hopping analysis. Molecules, 30 Aug 2018, 23 (9), 2183. 4.1 MB. https://doi.org/10.3390/molecules23092183 #Δ9-THC
EMCDDA. Report on the risk assessment of methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA), European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2018. 736 kB. #Δ9-THC IR,UV
EMCDDA. Report on the risk assessment of methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA), European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Mar 2017. 765 kB. #Δ9-THC IR,UV
Chicca, A; Schafroth, MA; Reynoso-Moreno, I; Erni, R; Petrucci, V; Carreira, EM; Gertsch, J. Uncovering the psychoactivity of a cannabinoid from liverworts associated with a legal high. Sci. Adv., 1 Oct 2018, 4 (10), eaat2166. 4.7 MB. https://doi.org/10.1126/sciadv.aat2166 #Δ9-trans-THC LC,MS,NMR,IR,other
Ujváry, I. The bumpy road ahead for forensic scientists. Synthetic cannabinoids to (unwel)come. Spice II Plus, 5 Jun 2014. 405 kB. #Δ9-THC
Banister, SD; Stuart, J; Conroy, T; Longworth, M; Manohar, M; Beinat, C; Wilkinson, SM; Kevin, RC; Hibbs, DE; Glass, M; Connor, M; McGregor, IS; Kassiou, M. Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. Forensic Toxicol., 1 Jul 2015, 33 (2), 355–366. 931 kB. https://doi.org/10.1007/s11419-015-0282-9 #Δ9-THC GC,MS,NMR,IR,UV,other
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: Evolution. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 191-226. 1.2 MB. https://doi.org/10.1007/164_2018_144 #1
Wilkinson, SM; Banister, SD; Kassiou, M. Bioisosteric fluorine in the clandestine design of synthetic cannabinoids. Aust. J. Chem., 10 Feb 2015, 68 (1), 4–8. 451 kB. https://doi.org/10.1071/CH14198 #1
Weissman, A; Milne, GM; Melvin, LS. Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol. J. Pharmacol. Exp. Ther., 1 Nov 1982, 223 (2), 516–523. 2.8 MB. #Δ9-THC
Passie, T; Brandt, SD. Self-experiments with psychoactive substances: A historical perspective. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 69-110. 563 kB. https://doi.org/10.1007/164_2018_177 #Cannabis
Banister, SD; Kumar, KK; Kumar, V; Kobilka, BK; Malhotra, SV. Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain. Med. Chem. Commun., 22 May 2019, 10 (5), 647–659. 810 kB. https://doi.org/10.1039/C8MD00595H #3
Sharma, R; Nikas, SP; Guo, JJ; Mallipeddi, S; Wood, JT; Makriyannis, A. C-Ring cannabinoid lactones: A novel cannabinergic chemotype. ACS Med. Chem. Lett., 10 Apr 2014, 5 (4), 400–404. 255 kB. https://doi.org/10.1021/ml4005304 #1
Meyers-Riggs, B. Alkylated naphthoylindoles. countyourculture, countyourculture: rational exploration of the underground, 1 Nov 2010. #THC
Meyers-Riggs, B. Phytocannabinoids. countyourculture, countyourculture: rational exploration of the underground, 26 Oct 2010. #THC
Banister, SD; Arnold, JC; Connor, M; Glass, M; McGregor, IS. Dark classics in chemical neuroscience: Δ9-Tetrahydrocannabinol. ACS Chem. Neurosci., 15 May 2019, 10 (5), 2160–2175. 1.8 MB. https://doi.org/10.1021/acschemneuro.8b00651 #1a
Patel, M; Manning, JJ; Finlay, DB; Javitch, JA; Banister, SD; Grimsey, NL; Glass, M. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. Biochem. Pharmacol., 1 May 2020, 175 113871. 1.9 MB. https://doi.org/10.1016/j.bcp.2020.113871 #THC
Alam, RM; Keating, JJ. Adding more “spice” to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists. Drug Test. Anal., 1 Mar 2020, 12 (3), 297–315. 2.8 MB. https://doi.org/10.1002/dta.2752 #11 Structure 71 has a single bond where a double bond belongs
Al-Zoubi; Morales; Reggio. Structural Insights into CB1 Receptor Biased Signaling. Int. J. Mol. Sci., 13 Apr 2019, 20 (8), 1837. 3.4 MB. https://doi.org/10.3390/ijms20081837 #Δ9-THC
Longworth, M; Reekie, TA; Blakey, K; Boyd, R; Connor, M; Kassiou, M. New-generation azaindole-adamantyl-derived synthetic cannabinoids. Forensic Toxicol., 1 Jul 2019, 37 (2), 350–365. 1.3 MB. https://doi.org/10.1007/s11419-019-00466-1 #1
Åstrand, A; Guerrieri, D; Vikingsson, S; Kronstrand, R; Green, H. In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT1A, and 5-HT2A receptors—On-target receptor potency and efficacy, and off-target effects. Forensic Sci. Int., 1 Dec 2020, 317, 110553. 1.7 MB. https://doi.org/10.1016/j.forsciint.2020.110553 #THC
Piggee, C. Investigating a not-so-natural high. Anal. Chem., 1 May 2009, 81 (9), 3205-3207. 150 kB. https://doi.org/10.1021/ac900564u #THC
Koppenhaver, D; Belton, J; Bonetti, J. Marijuana extraction using butane and the winterization step. JCLIC, 1 Mar 2016, 26 (2), 10-15. 1.6 MB. GC,MS
Churchill, KT. Synthetic tetrahydrocannabinol. J. Forensic Sci., 1 Jul 1983, 28 (3), 762–772. 352 kB. https://doi.org/10.1520/JFS11571J #Δ9-trans-THC GC,MS,NMR
Worob, A; Wenthur, C. DARK classics in chemical neuroscience: Synthetic cannabinoids (Spice/K2). ACS Chem. Neurosci., 2 Dec 2020, 11 (23), 3881–3892. 1.5 MB. https://doi.org/10.1021/acschemneuro.9b00586 #1
Brimblecombe, RW; Pinder, RM. Hallucinogenic agents, Wright-Scientechnica, Bristol, UK, 1 Jan 1975. 46.2 MB. #5.5,5.6
Shulgin, AT. Recent developments in cannabis chemistry. J. Psychoactive Drugs, 1 Oct 1968, 2 (1), 15–29. 1.3 MB. https://doi.org/10.1080/02791072.1968.10524397 #II
Banister, SD; Wilkinson, SM; Longworth, M; Stuart, J; Apetz, N; English, K; Brooker, L; Goebel, C; Hibbs, DE; Glass, M; Connor, M; McGregor, IS; Kassiou, M. The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse. ACS Chem. Neurosci., 17 Jul 2013, 4 (7), 1081–1092. 2.7 MB. https://doi.org/10.1021/cn400035r #1 MS,NMR